<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Aust Prescr</journal-id><journal-id journal-id-type="iso-abbrev">Aust Prescr</journal-id><journal-id journal-id-type="publisher-id">AP</journal-id><journal-title-group><journal-title>Australian Prescriber</journal-title></journal-title-group><issn pub-type="ppub">0312-8008</issn><issn pub-type="epub">1839-3942</issn><publisher><publisher-name>NPS MedicineWise</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31937986</article-id><article-id pub-id-type="pmc">6954872</article-id><article-id pub-id-type="publisher-id">austprescr-42-180</article-id><article-id pub-id-type="doi">10.18773/austprescr.2019.069</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letters to the Editor</subject></subj-group></article-categories><title-group><article-title>When should treatment be started for hypertension?</article-title></title-group><pub-date pub-type="epub"><day>02</day><month>12</month><year>2019</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2019</year></pub-date><volume>42</volume><issue>6</issue><fpage>180</fpage><lpage>181</lpage><permissions><copyright-statement>(c) NPS MedicineWise 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>NPS MedicineWise</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" specific-use="CC BY-NC-ND 4.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.</license-p></license></permissions><related-article related-article-type="commentary-article" id="d35e63" ext-link-type="doi" xlink:href="10.18773/austprescr.2019.038" journal-id="Aust Prescr" journal-id-type="nlm-ta" vol="42" page="127"/></article-meta></front><sub-article id="sa1" article-type="letter"><front><journal-meta><journal-id journal-id-type="publisher-id">AP</journal-id><journal-id journal-id-type="nlm-ta">Aust Prescr</journal-id><journal-title-group><journal-title>Australian Prescriber</journal-title><abbrev-journal-title abbrev-type="pubmed">Aust. Prescr.</abbrev-journal-title></journal-title-group><issn pub-type="ppub">0312-8008</issn><issn pub-type="epub">1839-3942</issn><publisher><publisher-name>NPS MedicineWise</publisher-name></publisher></journal-meta><article-meta><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Letter to the Editor</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gabb</surname><given-names>Genevieve</given-names></name><role>Senior staff specialist</role><xref ref-type="aff" rid="aff-1-1">1</xref></contrib><contrib contrib-type="author"><name><surname>Arnolda</surname><given-names>Leonard</given-names></name><role>Professor and Clinical Director</role><xref ref-type="aff" rid="aff-1-2">2</xref></contrib><aff id="aff-1-1"><label>1</label>Royal Adelaide Hospital, SA</aff><aff id="aff-1-2"><label>2</label>Illawarra Health and Medical Research Institute, University of Wollongong, NSW</aff></contrib-group><author-notes><fn id="afn-1-1"><p><italic>Dr Genevieve Gabb is a member of the Advisory Editorial Panel of</italic> Australian Prescriber, <italic>as representative of the High Blood Pressure Research Council of Australia.</italic></p></fn></author-notes><pub-date pub-type="epub"><day>02</day><month>12</month><year>2019</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2019</year></pub-date></article-meta></front><body><p>The article by Emily Atkins and Vlado Perkovic1 provides a welcome review of contemporary issues regarding blood pressure and vascular risk. Understanding blood pressure and its relationship to premature morbidity and mortality, and the use of effective interventions, has been a major success of the last 100 years. Yet, areas of uncertainty remain.</p><p>In contrast to previous definitions, the new, lower definition of hypertension adopted in recent US guidelines<xref rid="r-1-2" ref-type="bibr">2</xref> is based on the level of blood pressure where there is increased cardiovascular risk (observational data), rather than where treatment (interventional data) has demonstrated a net benefit. The recent article<xref rid="r-1-1" ref-type="bibr">1</xref> suggests that antihypertensive treatment may be worthwhile at a systolic blood pressure of less than 140 mmHg. However, there is little direct evidence to support this in patients without established vascular disease. The SPRINT trial<xref rid="r-1-3" ref-type="bibr">3</xref> is not informative for treatment thresholds, as 90% of the patients were established on therapy before enrolment. In contrast, the HOPE 3 trial<xref rid="r-1-4" ref-type="bibr">4</xref> demonstrated that baseline blood pressure was a significant determinant of risk reduction in intermediate-risk individuals. Those with higher blood pressure (systolic &#x0003e;143.5 mmHg) benefited from therapy, while those with lower blood pressure did not. A well-designed meta-analysis (incorporating the PICO elements of patient population, intervention, comparator and outcome) also suggests a treatment benefit with a threshold of 140 mmHg systolic.<xref rid="r-1-5" ref-type="bibr">5</xref></p><p>A careful approach is also needed in people with elevated blood pressure, who could, by virtue of age and sex, be considered low risk. Early clinical trials,<xref rid="r-1-6" ref-type="bibr">6</xref> where blood pressures were markedly elevated, had very high event rates, and very low numbers needed to treat (NNT=2) to prevent one event over 12 months. It is important to understand, particularly for younger doctors who may have limited personal experience with managing accelerated or malignant hypertension,<xref rid="r-1-7" ref-type="bibr">7</xref>,<xref rid="r-1-8" ref-type="bibr">8</xref> that hypertension can be a disease, as well as a risk factor.</p><p>Rather than the unnecessarily polarising view that a cardiovascular risk-based approach is best for determining when to start antihypertensive therapy, a more nuanced approach is helpful. Decisions on initiating antihypertensives should be based on both blood pressure and risk, as has been advocated in Australian blood pressure guidelines for some years.<xref rid="r-1-9" ref-type="bibr">9</xref></p></body><back><ref-list><title>REFERENCES</title><ref id="r-1-1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atkins</surname><given-names>ER</given-names></name><name><surname>Perkovic</surname><given-names>V</given-names></name></person-group>
<article-title>Blood pressure: at what level is treatment worthwhile?</article-title>
<source>Aust Prescr</source>
<year>2019</year>;<volume>42</volume>:<fpage>127</fpage>-<lpage>30</lpage>. <pub-id pub-id-type="doi">10.18773/austprescr.2019.038</pub-id><pub-id pub-id-type="pmid">31427843</pub-id></mixed-citation></ref><ref id="r-1-2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whelton</surname><given-names>PK</given-names></name><name><surname>Carey</surname><given-names>RM</given-names></name><name><surname>Aronow</surname><given-names>WS</given-names></name><name><surname>Casey</surname><given-names>DE</given-names><suffix>Jr</suffix></name><name><surname>Collins</surname><given-names>KJ</given-names></name><name><surname>Dennison Himmelfarb</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>2017 ACC/AHA/AAPA/ABC/ ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines</article-title>. <source>J Am Coll Cardiol</source>
<year>2018</year>;<volume>71</volume>:<fpage>e127</fpage>-<lpage>248</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2017.11.006</pub-id><pub-id pub-id-type="pmid">29146535</pub-id></mixed-citation></ref><ref id="r-1-3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></name><name><surname>Williamson</surname><given-names>JD</given-names></name><name><surname>Whelton</surname><given-names>PK</given-names></name><name><surname>Snyder</surname><given-names>JK</given-names></name><name><surname>Sink</surname><given-names>KM</given-names></name><name><surname>Rocco</surname><given-names>MV</given-names></name><etal/><collab>SPRINT Research Group</collab></person-group>
<article-title>A randomized trial of intensive versus standard blood-pressure control</article-title>. <source>N Engl J Med</source>
<year>2015</year>;<volume>373</volume>:<fpage>2103</fpage>-<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1511939</pub-id><pub-id pub-id-type="pmid">26551272</pub-id></mixed-citation></ref><ref id="r-1-4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lonn</surname><given-names>EM</given-names></name><name><surname>Bosch</surname><given-names>J</given-names></name><name><surname>L&#x000f3;pez-Jaramillo</surname><given-names>P</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Pais</surname><given-names>P</given-names></name><etal/><collab>HOPE-3 Investigators</collab></person-group>
<article-title>HOPE-3 Investigators. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease</article-title>. <source>N Engl J Med</source>
<year>2016</year>;<volume>374</volume>:<fpage>2009</fpage>-<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1600175</pub-id><pub-id pub-id-type="pmid">27041480</pub-id></mixed-citation></ref><ref id="r-1-5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunstr&#x000f6;m</surname><given-names>M</given-names></name><name><surname>Carlberg</surname><given-names>B</given-names></name></person-group>
<article-title>Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis</article-title>. <source>JAMA Intern Med</source>
<year>2018</year>;<volume>178</volume>:<fpage>28</fpage>-<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1001/jamainternmed.2017.6015</pub-id><pub-id pub-id-type="pmid">29131895</pub-id></mixed-citation></ref><ref id="r-1-6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Veterans Administration Cooperative Study Group on Antihypertensive Agents</collab></person-group>
<article-title>Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg</article-title>. <source>JAMA</source>
<year>1967</year>;<volume>202</volume>:<fpage>1028</fpage>-<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1001/jama.1967.03130240070013</pub-id><pub-id pub-id-type="pmid">4862069</pub-id></mixed-citation></ref><ref id="r-1-7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keith</surname><given-names>NM</given-names></name><name><surname>Wagener</surname><given-names>HP</given-names></name><name><surname>Kernohan</surname><given-names>JW</given-names></name></person-group>
<article-title>The syndrome of malignant hypertension</article-title>. <source>Arch Intern Med (Chic)</source>
<year>1928</year>;<volume>41</volume>:<fpage>141</fpage>-<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1001/archinte.1928.00130140003001</pub-id></mixed-citation></ref><ref id="r-1-8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kincaid-Smith</surname><given-names>P</given-names></name><name><surname>McMICHAEL</surname><given-names>J</given-names></name><name><surname>Murphy</surname><given-names>EA</given-names></name></person-group>
<article-title>The clinical course and pathology of hypertension with papilloedema (malignant hypertension)</article-title>. <source>Q J Med</source>
<year>1958</year>;<volume>27</volume>:<fpage>117</fpage>-<lpage>53</lpage>.<pub-id pub-id-type="pmid">13506014</pub-id></mixed-citation></ref><ref id="r-1-9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabb</surname><given-names>GM</given-names></name><name><surname>Mangoni</surname><given-names>AA</given-names></name><name><surname>Anderson</surname><given-names>CS</given-names></name><name><surname>Cowley</surname><given-names>D</given-names></name><name><surname>Dowden</surname><given-names>JS</given-names></name><name><surname>Golledge</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Guideline for the diagnosis and management of hypertension in adults - 2016</article-title>. <source>Med J Aust</source>
<year>2016</year>;<volume>205</volume>:<fpage>85</fpage>-<lpage>9</lpage>. <pub-id pub-id-type="doi">10.5694/mja16.00526</pub-id><pub-id pub-id-type="pmid">27456450</pub-id></mixed-citation></ref></ref-list></back></sub-article><sub-article id="sa2" article-type="letter"><front><journal-meta><journal-id journal-id-type="publisher-id">AP</journal-id><journal-id journal-id-type="nlm-ta">Aust Prescr</journal-id><journal-title-group><journal-title>Australian Prescriber</journal-title><abbrev-journal-title abbrev-type="pubmed">Aust. Prescr.</abbrev-journal-title></journal-title-group><issn pub-type="ppub">0312-8008</issn><issn pub-type="epub">1839-3942</issn><publisher><publisher-name>NPS MedicineWise</publisher-name></publisher></journal-meta><article-meta><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Letter to the Editor</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wing,</surname><given-names>Lindon</given-names></name><role>Emeritus Professor</role><xref ref-type="aff" rid="aff-2-1">1</xref></contrib><aff id="aff-2-1"><label>1</label><institution>Flinders University</institution>, <addr-line>Adelaide, SA</addr-line></aff></contrib-group><author-notes><fn id="afn-2-1"><p>Lindon Wing is Chair of the Management Committee of the Second Australian National Blood Pressure Study.</p></fn></author-notes><pub-date pub-type="epub"><day>02</day><month>12</month><year>2019</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2019</year></pub-date></article-meta></front><body><p>The recent article<xref rid="r-2-1a" ref-type="bibr">1a</xref> predominantly discusses blood pressure treatment targets, not thresholds. The recommendations are based largely on the SPRINT study<xref rid="r-2-2a" ref-type="bibr">2a</xref> and the recent US guidelines.<xref rid="r-2-3a" ref-type="bibr">3a</xref> The authors suggest, quoting one reference, that blood pressure measurement in SPRINT (automated office blood pressure) equates to usual clinic blood pressure measurement. However, the majority opinion is that systolic blood pressure measured by automated office blood pressure is 10&#x02013;20 mmHg lower than usual clinic blood pressure,<xref rid="r-2-4a" ref-type="bibr">4a</xref>,<xref rid="r-2-5a" ref-type="bibr">5a</xref> which has been used in all the clinical trials that provide the evidence base for the treatment of hypertension. In SPRINT, achieving systolic blood pressure less than 120 mmHg was also associated with serious treatment-related adverse events. SPRINT is therefore not a suitable study on which to base major treatment recommendations.</p><p>In contrast, the recent European hypertension guidelines5a have provided a well-argued case that treatment to lower blood pressure with both lifestyle change and drug therapy is of benefit if the &#x02018;clinic&#x02019; systolic blood pressure is more than 140 mmHg, across the range of blood pressures, cardiovascular risk, comorbidity, sex, ethnicity and age up to 80 years. This was based on available evidence including the SPRINT trial. The European guidelines also demonstrate the lack of evidence for initiating treatment if systolic blood pressure is 130&#x02013;140 mmHg, except possibly for those at very high cardiovascular risk and with established cardiovascular disease.</p><p>Target systolic blood pressure should initially be less than 140 mmHg and, if tolerated, less than 130 mmHg but not less than 120 mmHg. In my opinion the European recommendations are more broadly applicable to the management of hypertension in Australia than the recommendations given in the article.</p></body><back><ref-list><title>REFERENCES</title><ref id="r-2-1a"><label>1a</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atkins</surname><given-names>ER</given-names></name><name><surname>Perkovic</surname><given-names>V</given-names></name></person-group>
<article-title>Blood pressure: at what level is treatment worthwhile?</article-title>
<source>Aust Prescr</source>
<year>2019</year>;<volume>42</volume>:<fpage>127</fpage>-<lpage>30</lpage>. <pub-id pub-id-type="doi">10.18773/austprescr.2019.038</pub-id><pub-id pub-id-type="pmid">31427843</pub-id></mixed-citation></ref><ref id="r-2-2a"><label>2a</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></name><name><surname>Williamson</surname><given-names>JD</given-names></name><name><surname>Whelton</surname><given-names>PK</given-names></name><name><surname>Snyder</surname><given-names>JK</given-names></name><name><surname>Sink</surname><given-names>KM</given-names></name><name><surname>Rocco</surname><given-names>MV</given-names></name><etal/><collab>SPRINT Research Group</collab></person-group>
<article-title>A randomized trial of intensive versus standard blood-pressure control</article-title>. <source>N Engl J Med</source>
<year>2015</year>;<volume>373</volume>:<fpage>2103</fpage>-<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1511939</pub-id><pub-id pub-id-type="pmid">26551272</pub-id></mixed-citation></ref><ref id="r-2-3a"><label>3a</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whelton</surname><given-names>PK</given-names></name><name><surname>Carey</surname><given-names>RM</given-names></name><name><surname>Aronow</surname><given-names>WS</given-names></name><name><surname>Casey</surname><given-names>DE</given-names><suffix>Jr</suffix></name><name><surname>Collins</surname><given-names>KJ</given-names></name><name><surname>Dennison Himmelfarb</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>2017 ACC/AHA/AAPA/ABC/ ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines</article-title>. <source>J Am Coll Cardiol</source>
<year>2018</year>;<volume>71</volume>:<fpage>e127</fpage>-<lpage>248</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2017.11.006</pub-id><pub-id pub-id-type="pmid">29146535</pub-id></mixed-citation></ref><ref id="r-2-4a"><label>4a</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myers</surname><given-names>MG</given-names></name><name><surname>Godwin</surname><given-names>M</given-names></name><name><surname>Dawes</surname><given-names>M</given-names></name><name><surname>Kiss</surname><given-names>A</given-names></name><name><surname>Tobe</surname><given-names>SW</given-names></name><name><surname>Kaczorowski</surname><given-names>J</given-names></name></person-group>
<article-title>Measurement of blood pressure in the office: recognizing the problem and proposing the solution</article-title>. <source>Hypertension</source>
<year>2010</year>;<volume>55</volume>:<fpage>195</fpage>-<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.109.141879</pub-id><pub-id pub-id-type="pmid">20038756</pub-id></mixed-citation></ref><ref id="r-2-5a"><label>5a</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>B</given-names></name><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>Spiering</surname><given-names>W</given-names></name><name><surname>Agabiti Rosei</surname><given-names>E</given-names></name><name><surname>Azizi</surname><given-names>M</given-names></name><name><surname>Burnier</surname><given-names>M</given-names></name><etal/><collab>Authors/Task Force Members</collab></person-group>
<article-title>2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension</article-title>. <source>J Hypertens</source>
<year>2018</year>;<volume>36</volume>:<fpage>1953</fpage>-<lpage>2041</lpage>. <pub-id pub-id-type="doi">10.1097/HJH.0000000000001940</pub-id><pub-id pub-id-type="pmid">30234752</pub-id></mixed-citation></ref></ref-list></back></sub-article><sub-article id="sa3" article-type="letter"><front><journal-meta><journal-id journal-id-type="publisher-id">AP</journal-id><journal-id journal-id-type="nlm-ta">Aust Prescr</journal-id><journal-title-group><journal-title>Australian Prescriber</journal-title><abbrev-journal-title abbrev-type="pubmed">Aust. Prescr.</abbrev-journal-title></journal-title-group><issn pub-type="ppub">0312-8008</issn><issn pub-type="epub">1839-3942</issn><publisher><publisher-name>NPS MedicineWise</publisher-name></publisher></journal-meta><article-meta><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Authors&#x02019; response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Atkins</surname><given-names>Emily</given-names></name><role>Research fellow</role><xref ref-type="aff" rid="aff-3-1">1</xref></contrib><contrib contrib-type="author"><name><surname>Perkovic</surname><given-names>Vlado</given-names></name><role>Professor</role><xref ref-type="aff" rid="aff-3-1">1</xref></contrib><aff id="aff-3-1"><label>1</label>The George Institute for Global Health, UNSW Sydney</aff></contrib-group><pub-date pub-type="epub"><day>02</day><month>12</month><year>2019</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2019</year></pub-date></article-meta></front><body><p>Emily Atkins and Vlado Perkovic, the authors of the article, comment:</p><p>We thank the letter writers for their responses and welcome the discussion.</p><p>A key issue is their suggested separation of treatment thresholds from treatment targets. We disagree with this distinction, and believe that blood pressure targets and thresholds should be considered consistently, once a decision to intervene is reached. We agree that blood pressure treatment is worthwhile in hypertensive urgencies or emergencies, and blood pressure should be considered separately in this specific context.</p><p>We strongly believe SPRINT should guide blood pressure treatment approaches. The small increase in adverse events was clearly outweighed by a substantive reduction in cardiovascular events <italic>and</italic> all-cause mortality. It is criticised for the rigorous approach to blood pressure measurement, but we believe this careful measurement is a strength and would advocate for its recommendation and incorporation in guidelines, as has happened in US and Canadian guidelines.<xref rid="r-3-1b" ref-type="bibr">1b</xref>,<xref rid="r-3-2b" ref-type="bibr">2b</xref> We believe this is a small ask given patients are committed to potentially lifelong therapy.</p><p>Genevieve Gabb and Leonard Arnolda highlighted a meta-analysis. However, this did not exclude trials of dual inhibition of the renin&#x02013;angiotensin&#x02013;aldosterone system, which has minimal effects on blood pressure, substantial toxicity, and is contraindicated in guidelines. They highlight the HOPE 3 heterogeneity by baseline blood pressure, but we note the blood pressure reduction achieved in this trial was only 3 mmHg, limiting power. The 95% confidence intervals for the treatment estimate are still consistent with a 19% risk reduction even for participants in the lowest blood pressure tertile. We agree additional data would be helpful.</p><p>We believe targeting systolic blood pressure less than 120 mmHg in high-risk people will ensure maximal cardiovascular protection if it is tolerated and appropriate for the individual patient.</p></body><back><ref-list><title>REFERENCES</title><ref id="r-3-1b"><label>1b</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muntner</surname><given-names>P</given-names></name><name><surname>Shimbo</surname><given-names>D</given-names></name><name><surname>Carey</surname><given-names>RM</given-names></name><name><surname>Charleston</surname><given-names>JB</given-names></name><name><surname>Gaillard</surname><given-names>T</given-names></name><name><surname>Misra</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Measurement of blood pressure in humans: a scientific statement from the American Heart Association</article-title>. <source>Hypertension</source>
<year>2019</year>;<volume>73</volume>:<fpage>e35</fpage>-<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1161/HYP.0000000000000087</pub-id><pub-id pub-id-type="pmid">30827125</pub-id></mixed-citation></ref><ref id="r-3-2b"><label>2b</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nerenberg</surname><given-names>KA</given-names></name><name><surname>Zarnke</surname><given-names>KB</given-names></name><name><surname>Leung</surname><given-names>AA</given-names></name><name><surname>Dasgupta</surname><given-names>K</given-names></name><name><surname>Butalia</surname><given-names>S</given-names></name><name><surname>McBrien</surname><given-names>K</given-names></name><etal/><collab>Hypertension Canada</collab></person-group>
<article-title>Hypertension Canada. Hypertension Canada&#x02019;s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children</article-title>. <source>Can J Cardiol</source>
<year>2018</year>;<volume>34</volume>:<fpage>506</fpage>-<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.cjca.2018.02.022</pub-id><pub-id pub-id-type="pmid">29731013</pub-id></mixed-citation></ref></ref-list></back></sub-article></article>